Several studies have been conducted on the application of gene therapies using Ad5-based vaccines for the treatment of cancer or chronic virus infections, which have shown that the immunogenicity responses specific for Ad proteins and for transgene-encoded proteins induced by vaccines could have a significant impact on the efficacy of a recombinant Ad vaccine [23–25]. This evidence concerns the gene PSEN2 and cancer.